First Cell Therapy News Today

Media contact: Investor contact: ...

At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of care treatment regimens1 ...

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients

Landmark Study Aimed to Support FDA Registration of First Cell Therapy with Dual Anti-inflammatory and Lung Healing Mechanism of ActionOCEANSIDE, Calif.--(BUSINESS WIRE)--Therapeutic Solutions International announced today the launching of a double-blind, randomized, placebo controlled, multi-center, multi-nation, c...

Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16....